Pilaralisib

DB11772InvestigationalSmall molecule

Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). Pilaralisib has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors,...

Mechanism: Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). Activation of PI3K is a frequent event in human tumors, promoting tumor cell growth, survival, and resistance to chemotherapy and radiotherapy. Inactivation of PI3K has been shown to inhibit growth and induce apoptosis (programmed cell death) in tumor cells.
Curator reviewed
Formula / weight: C₂₅H₂₅ClN₆O₄S · 541.02 g/mol (avg)
Code names: SAR-245408 · XL-147

Resolves to

Compound

UNII60ES45KTMKCAS934526-89-3ChEMBLCHEMBL3360203PubChem56599306

Structure

InChIKeyQINPEPAQOBZPOF-UHFFFAOYSA-NSMILESCOC1=CC=C(Cl)C(NC2=C(NS(=O)(=O)C3=CC(NC(=O)C(C)(C)N)=CC=C3)N=C3C=CC=CC3=N2)=C1

Targets

P42336PIK3CAP48736PIK3CG

What you can answer from here — as of January 29, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pilaralisib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account